Cambridge Investment Research Advisors
ORGS

Cambridge Investment Research Advisors’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,833
Closed -$11K – 3539
2024
Q2 		$11K Hold
1,833
– – ﹤0.01% 3290
2024
Q1 		$15K Hold
1,833
– – ﹤0.01% 3274
2023
Q4 		$9K Hold
1,833
– – ﹤0.01% 3170
2023
Q3 		$11K Buy
+1,833
New +$16.4K ﹤0.01% 3108

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Cambridge Investment Research Advisors's ORGS Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of Orgenesis Inc. Common Stock (ORGS) in Q3 2024, closing a stake of 1,833 shares — an estimated $11K sold.

Cambridge Investment Research Advisors first reported a position in ORGS in Q3 2023 and held it in 4 quarters. The position peaked at $15K in Q1 2024. 11 funds tracked by Wall St. Rank hold ORGS as of Q3 2024.

  • Cambridge Investment Research Advisors reported no remaining Orgenesis Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,833 Orgenesis Inc. Common Stock shares in Q3 2024, an estimated $11K.
  • Cambridge Investment Research Advisors first reported a position in Orgenesis Inc. Common Stock in Q3 2023 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Orgenesis Inc. Common Stock position peaked at $15K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.